204 related articles for article (PubMed ID: 28224352)
1. HCV management in resource-constrained countries.
Lim SG
Hepatol Int; 2017 May; 11(3):245-254. PubMed ID: 28224352
[TBL] [Abstract][Full Text] [Related]
2. Treatment failure with DAA therapy: Importance of resistance.
Sarrazin C
J Hepatol; 2021 Jun; 74(6):1472-1482. PubMed ID: 33716089
[TBL] [Abstract][Full Text] [Related]
3. Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
Bailly F; Pradat P; Virlogeux V; Zoulim F
Dig Dis; 2015; 33(4):613-23. PubMed ID: 26159282
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.
Esteban R; Pineda JA; Calleja JL; Casado M; Rodríguez M; Turnes J; Morano Amado LE; Morillas RM; Forns X; Pascasio Acevedo JM; Andrade RJ; Rivero A; Carrión JA; Lens S; Riveiro-Barciela M; McNabb B; Zhang G; Camus G; Stamm LM; Brainard DM; Subramanian GM; Buti M
Gastroenterology; 2018 Oct; 155(4):1120-1127.e4. PubMed ID: 29958855
[TBL] [Abstract][Full Text] [Related]
5. Virological patterns of hepatitis C virus patients with failure to the current-generation direct-acting antivirals.
Pisaturo M; Starace M; Minichini C; De Pascalis S; Occhiello L; Fraia AD; Messina V; Sangiovanni V; Claar E; Coppola N;
Int J Antimicrob Agents; 2020 Sep; 56(3):106067. PubMed ID: 32599227
[TBL] [Abstract][Full Text] [Related]
6. Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.
Manoj Kumar ; Nayak SL; Gupta E; Kataria A; Sarin SK
Liver Int; 2018 Dec; 38(12):2137-2148. PubMed ID: 29676846
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment.
Goel A; Chen Q; Chhatwal J; Aggarwal R
J Gastroenterol Hepatol; 2018 Dec; 33(12):2029-2036. PubMed ID: 29864213
[TBL] [Abstract][Full Text] [Related]
8. Successful use of generic direct acting antiviral medications to treat hepatitis C-a New Zealand-wide study.
Aluzaite K; Fraser M; Johnson S; Giles H; Schultz M
N Z Med J; 2020 Nov; 133(1525):53-61. PubMed ID: 33223548
[TBL] [Abstract][Full Text] [Related]
9. Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study.
Akhil MS; Kirushnan B; Martin M; Arumugam K; Ganesh Prasad NK; Ravichandran R
Nephrology (Carlton); 2018 May; 23(5):446-452. PubMed ID: 28339162
[TBL] [Abstract][Full Text] [Related]
10. Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients.
Maughan A; Sadigh K; Angulo-Diaz V; Mandimika C; Villanueva M; Lim JK; Ogbuagu O
BMC Infect Dis; 2019 May; 19(1):378. PubMed ID: 31053098
[TBL] [Abstract][Full Text] [Related]
11. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
Buggisch P; Wursthorn K; Stoehr A; Atanasov PK; Supiot R; Lee J; Ting J; Petersen J
PLoS One; 2019; 14(4):e0214795. PubMed ID: 30946776
[TBL] [Abstract][Full Text] [Related]
12. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Hepatitis C Virus: An Update on Medications and Patient Education.
Molino S; Cottreau J
Orthop Nurs; 2019; 38(4):273-277. PubMed ID: 31343633
[TBL] [Abstract][Full Text] [Related]
14. Retreatment of Hepatitis C Virus-Infected Patients with Direct-Acting Antiviral Failures.
Pawlotsky JM
Semin Liver Dis; 2019 Jul; 39(3):354-368. PubMed ID: 31041789
[TBL] [Abstract][Full Text] [Related]
15. Sofosbuvir/Velpatasvir/Voxilaprevir: A Pan-Genotypic Direct-Acting Antiviral Combination for Hepatitis C.
Chahine EB; Kelley D; Childs-Kean LM
Ann Pharmacother; 2018 Apr; 52(4):352-363. PubMed ID: 29115151
[TBL] [Abstract][Full Text] [Related]
16. Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study.
Zeng QL; Xu GH; Zhang JY; Li W; Zhang DW; Li ZQ; Liang HX; Li CX; Yu ZJ
J Hepatol; 2017 Jun; 66(6):1123-1129. PubMed ID: 28189754
[TBL] [Abstract][Full Text] [Related]
17. High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in myanmar.
Hlaing NKT; Nangia G; Tun KT; Lin S; Maung MZ; Myint KT; Kyaw AMM; Maung ST; Sein Win S; Bwa AH; Loza BL; Win KM; Reddy KR
J Viral Hepat; 2019 Oct; 26(10):1186-1199. PubMed ID: 31104344
[TBL] [Abstract][Full Text] [Related]
18. Sofosbuvir/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C.
Chahine EB; Sucher AJ; Hemstreet BA
Ann Pharmacother; 2017 Jan; 51(1):44-53. PubMed ID: 27609942
[TBL] [Abstract][Full Text] [Related]
19. [Proposal for a simple scheme of direct-action antivirals for HCV treatment in a low budget public health system].
Valdez-Hernández P; Rodríguez-Aguilar EF; Páez-Zayas VM; Lizárraga-Gómez E; García-Juárez I
Salud Publica Mex; 2018; 60(6):738-740. PubMed ID: 30699280
[No Abstract] [Full Text] [Related]
20. Successful fourth line treatment of a relapse patient with chronic hepatitis C virus infection genotype 3a using sofosbuvir, glecaprevir/pibrentasvir, and ribavirin: a case report.
Bernhard B; Stickel F
Z Gastroenterol; 2020 May; 58(5):451-455. PubMed ID: 32392606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]